Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim (BI) Collaboration

OXFORD, United Kingdom and SAN JOSE, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, today announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies.